29F.1A12™-CP004单克隆抗体是原始29F.1A12™克隆号的重组嵌合型抗体。可变结构域序列与原始29F.1A12™克隆号相同,但是恒定区序列已经从大鼠IgG2a变为小鼠IgG1。29F.1A12™-CP004抗体像原始大鼠IgG2a抗体一样无Fc突变。
29F.1A12™-CP004单克隆抗体与小鼠PD-1(程序性死亡-1蛋白,也称为CD279)反应。PD-1是一种50-55 kDa的细胞表面受体,由Pdcd1基因编码,属于免疫球蛋白超家族的CD28家族。PD-1在CD4和CD8胸腺细胞以及活化的T和B淋巴细胞和骨髓细胞上瞬时表达。成功清除抗原后,PD-1表达下降。此外,Pdcd1 mRNA在前B细胞阶段发育中的B淋巴细胞中表达。PD-1的结构包括一个ITIM(免疫受体酪氨酸抑制基序),表明PD-1负调节TCR信号。PD-1通过结合它的两个配体PD-L1和PD-L2发出信号,这两个配体都是B7家族的成员。配体结合后,PD-1信号抑制T细胞活化,导致增殖、细胞因子产生和T细胞死亡减少。此外,已知PD-1在小鼠的外周耐受性和预防自身免疫性疾病中起关键作用,因为PD-1敲除动物表现出扩张性心肌病、脾肿大和外周耐受性丧失。诱导的PD-L1表达常见于许多肿瘤,包括鳞状细胞癌、结肠腺癌和乳腺腺癌。PD-L1过度表达导致肿瘤细胞对CD8 T细胞介导的裂解的抗性增加。在黑色素瘤的小鼠模型中,通过用阻断PD-L1和它的受体PD-1之间的相互作用,肿瘤生长可以暂时被抑制。目前PD-1是癌症免疫疗法的热门靶点之一。
产品详情:
产品名称 | RecombiMAb anti-mouse PD-1 (CD279) |
产品货号 | CP004 |
产品规格 | 1mg |
反应种属 | Mouse |
克隆号 | 29F.1A12™-CP004 |
同种型 | Mouse IgG1(switched from rat IgG2a) |
免疫原 | Recombinant PD-1-Ig fusion protein |
实验应用 | in vivo blocking of PD-1/PD-L signaling* in vitro PD-1 neutralization* Immunohistochemistry (frozen)* Immunofluorescence* Western blot* Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody |
产品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
纯度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
无菌处理 | 0.2 µm filtration |
纯化方式 | Protein G |
分子量 | 150 kDa |
小鼠病原检测 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存条件 | 抗体原液保存在4°C,不能冷冻保存。 |
推荐同型对照 | InVivoPlus mouse IgG1 isotype control, unknown specificity(货号BP0083) |
推荐抗体稀释液 | InVivoPure pH 7.0 Dilution Buffer(货号IP0070) |
该产品自上市已被多篇SCI文献引用,品质有保证,以下是部分已发表的文献引用:
应用 | 文章 |
体内PD-1/PD-L信号阻断 (in vivo blocking of PD-1/ PD-L signaling) | 1. Wang, W., et al. (2018). 'RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer' Cancer Cell 34(5): 757-774 e757. 2. Gordon, S. R., et al. (2017). 'PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity' Nature 545(7655): 495-499. 3. Koyama, S., et al. (2016). 'STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment' Cancer Res 76(5): 999-1008. |
体内PD-1/PD-L信号阻断, 流式细胞术 (in vivo blocking of PD-1/ PD-L signaling, Flow Cytometry) | 1.Koyama, S., et al. (2016). 'Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints' Nat Commun 7: 10501. |
体外PD-1中和 (in vitro PD-1 neutralization) | 1.Park, S. J., et al. (2014). 'Negative role of inducible PD-1 on survival of activated dendritic cells' J Leukoc Biol 95(4): 621-629. |
体内PD-1/PD-L信号阻断, 体外PD-1中和(in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization) | 1.Duraiswamy, J., et al. (2013). 'Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors' Cancer Res 73 (12): 3591-3603. |
流式细胞术 (Flow Cytometry) | 1.Good-Jacobson, K. L., et al. (2012). 'CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation' J Immunol 188(9): 4217-4225. |
更多产品详情请联系BioXCell 中国授权代理——欣博盛生物